IMPLANET News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

27.10.15	Implanet: Substantial Increase in Q3 2015 Revenue: +42% to €1,693 Thousand (Businesswire)
13.10.15	Implanet Announces the 10,000th Jazz Band Sold (Businesswire)
23.09.15	IMPLANET: New JAZZ Band FDA clearance expands posterior fixation system selection (Businesswire)
15.09.15	Implanet: 2015 first-half results (Businesswire)
28.07.15	IMPLANET: Spine Sales up 66% in H1 2015 (Businesswire)
16.06.15	Implanet Enrolls First Patient in a Major Multi-Center Clinical Study Led by the Ohio State University (Businesswire)
19.05.15	IMPLANET: CE Mark and FDA Clearance in the United States for New JAZZ Diameters (Businesswire)
28.04.15	Implanet: Q1 2015 Revenue: 78% Increase in Spine Sales (Businesswire)
20.04.15	Implanet Announces Definitive Clinical Results in a Comparative Study of the JAZZ Band in Idiopathic Scoliosis Surgery (Businesswire)
31.03.15	Implanet: 2014 Annual Results (Businesswire)
24.03.15	Implanet Announces Publication of a Cost Effectiveness Study of JAZZ™ Band in Adolescent Idiopathic Scoliosis (Businesswire)
18.03.15	Implanet Announces a Highly Successful Capital Increase with Preemptive Rights, Raising €11.2 Million (Businesswire)
18.02.15	Implanet announces a capital increase, with shareholders’ preferential subscription rights, of approximately €10m to finance its accelerated growth (Businesswire)
02.02.15	Implanet announces that it has been definitively granted intellectual protection for its JAZZ technology in Europe (Businesswire)
13.01.15	Implanet Announces the Filling of Its Registration Document (Businesswire)
07.01.15	IMPLANET: 2014 annual revenue: €7.0 million (Businesswire)
24.11.14	Implanet Stands out at the North American Spine Society (NASS) Annual Meeting and Signs Six New Distribution Agreements (Businesswire)
17.11.14	Implanet Joins the EnterNext© PEA-PME 150 Index (Businesswire)
12.11.14	Implanet Announces the Appointment of Brian Kwon, MD, as Medical Advisor for the United States (Businesswire)
27.10.14	IMPLANET : Strong 9-Month Revenue Growth of Proprietary Product Lines: +23% (Businesswire)
15.09.14	Implanet: 2014 First Half Results (Businesswire)
08.09.14	Implanet Presents the Clinical Results of its JAZZ Implant in Adolescent Scoliosis Surgery (Businesswire)
28.07.14	IMPLANET: Buoyant Growth in Revenue in 1H 2014: +21% to €4.0 Million (Businesswire)
17.07.14	IMPLANET: Nomination of an International Expert in Healthcare Strategy Advising to the Board of Directors (Businesswire)
10.07.14	Implanet Subscribes to a Contingent Equity Line with Kepler Cheuvreux (Businesswire)
12.05.14	IMPLANET: Major new distribution agreements in the United States (Businesswire)
28.04.14	IMPLANET: Q1 2014 Revenue of over €2.0 Million (Businesswire)
15.04.14	Implanet Strengthens Its Board by Appointing an International Sectorial Expert (Businesswire)
01.04.14	Implanet Confirms its PME-PEA Equity Savings Plan Eligibility (Businesswire)
31.03.14	Implanet Recruits a Sales Director in the United States to Support Its Growth Dynamic (Businesswire)
18.03.14	Implanet: 2013 Annual Results (Businesswire)
28.01.14	Implanet: 2013 Annual Revenue (Businesswire)
07.01.14	IMPLANET Announces Further Strategic Distribution Agreements and Recruitments in the United States (Businesswire)
16.12.13	Implanet Announces the Signing of a Distribution Agreement in Germany (Businesswire)
09.12.13	IMPLANET: 2014 Financial Calendar (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swisscom	527.00	2.33 %	K V
Holcim	95.34	1.21 %	K V
UBS Group	30.42	0.86 %	K V
Roche Hldg G	289.00	0.45 %	K V
Swiss Re	141.65	0.35 %	K V
Givaudan	3’850.00	-1.48 %	K V
Lonza Grp	603.80	-1.50 %	K V
Alcon	82.30	-1.53 %	K V
Geberit	508.00	-1.74 %	K V
Part Grp Hldg	1’386.00	-2.26 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu IMPLANET SA

Aktien Top/Flop

Meistgelesene Nachrichten